MiMedx Group (MDXG) Stock: Buy, Sell, or Hold?
MDXG - MiMedx Group, Inc
$3.88
-0.06 (-1.40%)
▼
5d:
-12.53%
30d:
-17.73%
90d:
-9.04%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Oct 28, 2026
4d
Get Alerted When MDXG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MDXG is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MDXG is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MDXG is currently trading at $3.88, which is considered oversold relative to its 30-day fair value range of $4.35 to $4.85. From a valuation perspective, the stock is trading at a premium (Forward PE: 37.4) compared to its historical average (26.8). At these levels, the market is pricing in 11.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MDXG is in a strong uptrend. Immediate support is located at $3.67, while resistance sits at $4.88.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.40 (+88.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MDXG is in a strong uptrend. Immediate support is located at $3.67, while resistance sits at $4.88.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.40 (+88.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.35 -
$4.85
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 88.3% below Wall St target ($7.40)
- NEUTRAL: Trading at premium valuation - market expects 11.8% growth which is achievable
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.35 -
$4.85
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.67
Resistance Level
$4.88
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
37.43
Wall Street Target
$7.40
(+88.3%)
Revenue Growth (YoY)
-34.7%
Earnings Growth (YoY)
99.5%
Profit Margin
1.8%
Valuation Premium vs History
+11.8% premium
PE vs Historical
37.4 vs 26.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+11.8%
(market-implied from PE analysis)
1-Year Target
$4.39
(+12%)
2-Year Target
$4.91
(+25%)
3-Year Target
$5.49
(+40%)
3-Yr Target (if PE normalizes)
(PE: 37→27)
PE COMPRESSION
$3.93
(+0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
Forward PE: 19.53 | Forward EPS (Implied): $0.20
Bull Case
$4.75
(+21%)
Analyst growth 15.0%, PE expands to 20.5
Base Case
$3.93
(0%)
Market implied 0.0%, PE stable at 19.5
Bear Case
$3.01
(-24%)
Severe decline -15.0%, PE contracts to 17.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 23, 2026 3:20 PM ET
Data refreshes hourly during market hours. Next update: 4:20 PM
Data refreshes hourly during market hours. Next update: 4:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDXG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 58 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 75 BUY |
